<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01995370</url>
  </required_header>
  <id_info>
    <org_study_id>021-TADD-1300-1</org_study_id>
    <secondary_id>000012180</secondary_id>
    <nct_id>NCT01995370</nct_id>
  </id_info>
  <brief_title>Cilostazol Stroke Prevention Study for Antiplatelet Combination</brief_title>
  <acronym>CSPS・com</acronym>
  <official_title>Cilostazol Stroke Prevention Study for Antiplatelet Combination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Japan Cardiovascular Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Japan Cardiovascular Research Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To examine the efficacy and safety of dual antiplatelet therapy (DAPT) including cilostazol
      (Pletaal OD Tablet ®) in comparison with antiplatelet monotherapy (excluding cilostazol) for
      secondary prevention of ischemic stroke in high-risk patients for stroke
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence of symptomatic ischemic stroke, with the symptoms lasting for at least 24 hours</measure>
    <time_frame>every 6 months</time_frame>
    <description>An &quot;ischemic stroke&quot; hereafter indicates a symptomatic ischemic stroke.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Any stroke [ischemic stroke (IS), intracerebral hemorrhage (ICH), subarachnoid hemorrhage (SAH)]</measure>
    <time_frame>every 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAH or ICH</measure>
    <time_frame>every 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IS or transient ischemic attack (TIA)</measure>
    <time_frame>every 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death from any cause</measure>
    <time_frame>every 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke (IS，ICH，SAH), myocardial infarction (MI), or vascular death</measure>
    <time_frame>every 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All vascular events: stroke, MI, and other vascular events</measure>
    <time_frame>every 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events and adverse drug reactions</measure>
    <time_frame>every 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe or life-threatening hemorrhage (GUSTO Criteria)</measure>
    <time_frame>every 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Noncardioembolic Cerebral Infarction</condition>
  <arm_group>
    <arm_group_label>Monotherapy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin (81mg or 100mg) or clopidogrel (50mg or 75mg) will be orally administered once daily.
The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DAPT group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cilostazol (100mg twice daily) will be orally administered in combination with aspirin (81 or 100mg once daily) or clopidogrel (50 or 75mg once daily).
The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin</intervention_name>
    <description>Aspirin (81mg or 100mg) will be orally administered once daily.The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.</description>
    <arm_group_label>Monotherapy group</arm_group_label>
    <arm_group_label>DAPT group</arm_group_label>
    <other_name>Bayaspirin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel</intervention_name>
    <description>Clopidogrel (50mg or 75mg) will be orally administered once daily.The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.</description>
    <arm_group_label>Monotherapy group</arm_group_label>
    <arm_group_label>DAPT group</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cilostazol</intervention_name>
    <description>Cilostazol (100mg twice daily) will be orally administered. The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.</description>
    <arm_group_label>DAPT group</arm_group_label>
    <other_name>Pletaal OD Tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a diagnosis of noncardioembolic IS that developed between 8 and 180 days
             before the start of the protocol treatment

          -  Patients with a responsible lesion identified by MRI

          -  Patients aged 20 to 85 years old when providing informed consent

          -  Patients taking clopidogrel or aspirin alone as antiplatelet therapy when providing
             informed consent

          -  Patients meeting at least one of the following criteria a−c:

               1. at least 50% stenosis of a major intracranial artery (to the level of A2, M2, or
                  P2)

               2. at least 50% stenosis of an extracranial artery (the common carotid
                  artery，internal carotid artery，vertebral artery，brachiocephalic artery，or
                  subclavian artery)

               3. Two or more of the following risk factors

                    -  Aged 65 years or more

                    -  Diabetes mellitus

                    -  Hypertension

                    -  Peripheral arterial disease

                    -  Chronic kidney disease

                    -  History of IS (excluding the index IS for this study)

                    -  History of ischemic heart disease

                    -  Smoking (only current smokers)

          -  Patients considered to be able to visit the study site for ambulatory care throughout
             the observation period

          -  Patients who provided written informed consent

        Exclusion Criteria:

          -  Patients with emboligenic heart disease

          -  Patients taking any anticoagulant agents

          -  Patients who cannot undergo MRI examination for reasons such as claustrophobia and
             implanted pacemaker

          -  Patients scheduled to undergo any surgery, such as percutaneous angioplasty, stent
             placement, and bypass grafting, during the study period

          -  Patients with a drug-eluting coronary stent implanted within one year

          -  Patients with a history of symptomatic non-traumatic intracranial hemorrhage, any
             other hemorrhagic disease (eg, active peptic ulcer), bleeding predisposition, or blood
             clotting disorders

          -  Patients with a history of hypersensitivity to cilostazol

          -  Patients with congestive heart failure or uncontrolled angina pectoris

          -  Patients with thrombocytopenia (platelet count ≦ 100,000/mm3)

          -  Patients with severe liver or renal dysfunction

          -  Women who are pregnant, breast-feeding, or of child-bearing potential

          -  Patients with a malignant tumor requiring treatment

          -  Patients who are taking aspirin, and meet any of the following criteria:

               -  History of hypersensitivity to aspirin or salicylic acid analogues

               -  Current peptic ulcer

               -  Aspirin-induced asthma or its history

          -  Patients who are taking clopidogrel, and meet the following criterion:

             ・History of hypersensitivity to clopidogrel

          -  Patients who are participating in any other clinical studies

          -  Patients considered by the investigator/subinvestigator to be unsuitable for
             participating in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takenori Yamaguchi, President emeritus</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cerebral and Cardiovascular Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Norio Aso</last_name>
    <phone>+81-6-6872-0010</phone>
    <email>jcrf-csps@jcvrf.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Minoru Ido</last_name>
    <phone>+81-6-4807-3015</phone>
    <email>prj-csps.cont.com@eps.co.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Japan Cardiovascular Research Foundation</name>
      <address>
        <city>Osaka</city>
        <zip>565-8565</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norio Aso</last_name>
      <phone>+81-6-6872-0010</phone>
      <email>jcrf-csps@jcvrf.jp</email>
    </contact>
    <contact_backup>
      <last_name>Minoru Ido</last_name>
      <phone>+81-6-4807-3015</phone>
      <email>prj-csps.cont.com@eps.co.jp</email>
    </contact_backup>
    <investigator>
      <last_name>Takenori Yamaguchi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2013</study_first_submitted>
  <study_first_submitted_qc>November 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2013</study_first_posted>
  <last_update_submitted>December 3, 2013</last_update_submitted>
  <last_update_submitted_qc>December 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Noncardioembolic cerebral infarction</keyword>
  <keyword>Dual antiplatelet therapy (DAPT)</keyword>
  <keyword>Cilostazol</keyword>
  <keyword>Aspirin</keyword>
  <keyword>Clopidogrel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Cilostazol</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

